# Telavancin Observational Use Registry (TOUR)

> **NCT02288234** · — · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 1063 (actual)

## Conditions studied

- Hospital Acquired Bacterial Pneumonia
- Complicated Skin and Skin Structure Infections
- Ventilator Associated Bacterial Pneumonia
- Gram Positive Infection

## Interventions

- **DRUG:** Vibativ

## Key facts

- **NCT ID:** NCT02288234
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-06
- **Final completion:** 2017-10
- **Target enrollment:** 1063 (ACTUAL)
- **Last updated:** 2019-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02288234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02288234, "Telavancin Observational Use Registry (TOUR)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02288234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*